Background: Colonoscopy is widely used in the Veterans Affairs (VA) health care system for colorectal cancer (CRC) prevention, but its effect on CRC mortality is unknown.
C
olonoscopy is the dominant method for colorectal cancer (CRC) screening in the United States (1) . It was first endorsed for this indication in 1997 on the basis of several observational studies and the concept that it would extend the benefits of sigmoidoscopic screening to the entire colon. Screening colonoscopy became a Medicare benefit in 2001, and its use has increased exponentially, with estimates of overall annual colonoscopy volume ranging from 11.5 to 14 million (2, 3) . However, screening colonoscopy is not supported by randomized controlled trials, and recent studies have questioned whether it offers incremental benefit over sigmoidoscopy in the proximal colon. Case-control studies in Canadian populations showed that colonoscopy was associated with reduced risk for death from left-sided but not right-sided CRC (4, 5) . Conversely, studies from Germany (6 -8) and the United States (9) reported that colonoscopy was associated with decreased incidence and mortality for both left-sided and right-sided CRC, although the benefit was less in the proximal colon. These inconsistent findings and variable degrees of protection against CRC have been partly attributed to operator-dependent quality factors (10) .
The Veterans Health Administration (VHA) is the largest integrated health care provider in the United States. The VHA system includes 170 medical centers and 1063 outpatient clinics, which serve nearly 9 million enrolled veterans each year. Use of colonoscopy for CRC screening in the VHA has been expanding; a more than 2-fold increase in use of screening colonoscopy and a decrease in use of sigmoidoscopy and double-contrast barium enema were noted between 1997 and 2003 (11) , and the VHA endorsed colonoscopy as a primary CRC screening option for patients aged 50 years or older in 2007. Despite these trends, it is unknown whether colonoscopy decreases CRC mortality among veterans and whether the effect varies on the basis of anatomical location of CRC.
Estimating colonoscopy effectiveness is important from an individual perspective. Veterans differ from the general population with regard to risk factors for colon neoplasia (male sex and cigarette smoking) and have higher CRC and adenoma prevalence (12) . From a systems perspective, the VHA is centralized and is less reliant on financial incentives for individual providers and may therefore provide a reference standard for other health care systems. In the context of increasing use of colonoscopy and its dominance as a CRC screening method in the United States, knowledge of its effect on important patient outcomes is critical to guide health care resource use and policy, both within the VHA and in other health care settings.
We conducted a case-control study using national Veterans Affairs (VA)-Centers for Medicare and Medicaid Services (CMS) administrative data to determine whether colonoscopy is associated with decreased CRC mortality in veterans and whether its effect differs by anatomical location of CRC.
METHODS
The study was approved by the Institutional Review Boards at Indiana University-Purdue University Indianapolis and Dartmouth Institute Dartmouth-Hitchcock Medical Center and by the Research and Development Committees of the Richard L. Roudebush VA Medical Center in Indianapolis, Indiana, and the VA Medical Center in White River Junction, Vermont.
Study Population
The sampling frame comprised veterans with inpatient and/or outpatient visits at any VA facility from 1997 to 2010. Definitions of case patients and control patients are broadly similar to those used in previous studies by Baxter and colleagues (4, 9) . To ensure that patients were representative of veterans who receive care predominantly in the VHA system (13), we included only veterans with at least 2 primary care visits at 1 VA facility in the 3 years before CRC diagnosis in case patients and before the corresponding index date in control patients.
Identification of Case Patients
Case patients were veterans who received a diagnosis of CRC when they were aged 50 years or older and died of CRC when they were aged 52 years or older.
Case patients were identified from 1 January 2002 to 31 December 2008 and died of CRC between 1 January 2002 and 31 December 2010. Patients with a diagnosis of CRC who died of other causes were not counted as case patients. Patients with a history of CRC or surgical resection of CRC before 1 January 2002 were excluded, as were those with Crohn disease, ulcerative colitis, or familial polyposis. Cancer was categorized as right-sided (cecum, ascending colon, hepatic flexure, or transverse colon) or left-sided (splenic flexure, descending colon, sigmoid colon, or rectum).
Identification of Control Patients
Control patients were assigned an index date that corresponded to the date of CRC diagnosis in their matched case patient. Control patients were veterans who were not diagnosed with CRC before the index date and did not die of the disease before 31 December 2010. For each case patient, we matched 4 control patients according to age (±1 year), sex, and VA medical center. Similar to case patients, control patients with a history of Crohn disease, ulcerative colitis, or familial polyposis were excluded. As in prior studies, control patients were alive at the time of death of a matched case patient (4, 9).
Exposure
The exposure was defined as receipt of colonoscopy between 1 January 1997 and 6 months before CRC diagnosis in case patients or the corresponding index date in control patients ( Figure) . If a case patient had undergone more than 1 colonoscopy during the exposure period, the first one was counted as the exposure. We performed subgroup analysis to determine exposure to screening colonoscopy, using an algorithm developed and validated in VA administrative data by El-Serag and colleagues (11) for classification of colonoscopy indication according to administrative codes. The algorithm defines screening colonoscopy on the basis of the absence of prior codes associated with gastrointestinal disorders (diagnostic indication) or a history of polyps (surveillance indication). The algorithm has sensitivity of about 70% and specificity of about 72%.
Confounding Factors
For all patients, we calculated a Charlson Comorbidity Index score (14, 15) based on 1 inpatient code or 2 or more outpatient codes separated by at least 30 days within the year before the index date (date of diagnosis for case patients and corresponding date for control patients) (16) . We measured duration of use, expressed as the number of days of aspirin, nonsteroidal anti-inflammatory drug (NSAID), and statin prescription. This was categorized as none, up to 3 years, 3 to 5 years, and more than 5 years. We adjusted for confounders that may affect CRC risk, including race; Charlson Comorbidity Index score; socioeconomic status; diabetes mellitus; cigarette smoking; family history of CRC; ischemic heart disease; cholecystectomy; and use of aspirin, NSAIDs, and statins. We measured the number of prostate-specific antigen measurements in 
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Data Sources

VA Central Cancer Registry (VACCR)
The VACCR was used to ascertain CRC diagnoses for case patients and exclusion of CRC among control patients. Cancer diagnoses within the VHA are submitted to the registry every 6 months. The VACCR includes demographic information, date of diagnosis, pathologic confirmation, cancer location within the colon and rectum, previous cancer, and stage of cancer. The registry has excellent sensitivity (17) .
VA Medical SAS Data Sets
These data sets contain national administrative data on all VA inpatient stays and outpatient encounters. The data were used to abstract patient-level information on performance and dates of colonoscopy, comorbidities, and primary care visits. Outpatient procedures are coded using Current Procedural Terminology and Healthcare Common Procedure Coding System codes. Inpatient procedures and diagnoses are coded according to the International Classification of Diseases, Ninth Revision, Clinical Modification.
Linked VA-CMS Data
These data were used to identify veterans who had colonoscopies in non-VA facilities for which CMS was the primary payer. Similar to the VA medical SAS data sets, the VA-CMS data contain inpatient and outpatient data, including diagnoses, procedure dates, and other information on health care use.
Department of Defense Suicide Data Registry
This registry was used to identify patients with CRC who died of their disease (case patients). The registry contains information on date and cause of death for all VA health system users, based on information from the National Death Index, which is the gold standard for 
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VA Pharmacy Benefits Management (PBM) Services
The PBM, which contains information on all outpatient prescriptions dispensed within the VHA since fiscal year 1999, was accessed to obtain information on exposure to aspirin, other NSAIDs, and statins from 1999 to the day before the index date.
Statistical Analysis
Descriptive statistics for demographic and clinical variables were calculated for all patients. We used the chi-square test or the Fisher exact test to compare proportions and the t test to compare continuous variables. The primary analysis was based on the matched quintuplets (1 case patient and 4 control patients). We performed conditional logistic regression with adjustment for potential confounders to calculate odds ratios (ORs) and 95% CIs for death from CRC by exposure to colonoscopy. This calculation was done using colonoscopy as the exposure and was then repeated with screening colonoscopy as the exposure (based on ElSerag and colleagues' algorithm [11] ). To investigate the association between exposure to colonoscopy and anatomical location of CRC (right-or left-sided), we recalculated ORs for death from CRC based on anatomical location. To assess the effect of varying definitions of control patients, we performed a sensitivity analysis in which control patients could have been diagnosed with CRC before the index date. Another sensitivity analysis was done to determine the effect of varying the period between CRC diagnosis (or corresponding index date in control patients) and exposure to colonoscopy, using intervals of 3, 12, or 24 months. All analyses were performed using SAS, version 9.2 (SAS Institute).
Role of the Funding Source
This study was supported by a VA Clinical Science Research & Development Grant. The VA was not involved in the design, conduct, or analysis of the study or the decision to submit the manuscript for publication.
RESULTS
A total of 4964 case patients and 19 856 control patients were identified. The mean age was 70.7 years (SD, 10.0), and 99.3% were male. Clinical characteristics of the patients are shown in Table 1 . Case patients had higher comorbidity burden, as reflected by higher mean Charlson Comorbidity Index scores. A significantly smaller proportion of case patients were exposed to colonoscopy (13.5% vs. 26.4%; P < 0.001). A total of 668 case patients and 5250 control patients were exposed to colonoscopy; the indication was diagnostic in 68.7% and 60.9%, screening in 15.3% and 21.3%, and surveillance in 16.0% and 17.8%, respectively (P < 0.001). Median time between colonoscopy and CRC diagnosis was 43.5 months (range, 6 to 141 months) among case patients. The proportions of patients who underwent colonoscopy for a screening indication were 8 
DISCUSSION
In this study using national VA-Medicare data, colonoscopy was associated with a 61% reduction in CRC mortality among veterans. This reduction was observed for both left-and right-sided CRC, although the association was weaker for right-sided cancer (46% vs. 72% mortality reduction). These trends were also observed in the screening colonoscopy subgroup.
Several studies have assessed the association between colonoscopy and CRC incidence and mortality (4 -9, 18 -25) . Population-based case-control studies from Ontario (4) and Manitoba (5) initially reported that colonoscopy was associated with a 47% to 67% reduction in distal CRC mortality risk but afforded no protection against proximal colon cancer. These findings have been partly attributed to characteristics of the Canadian system, where colonoscopy is performed predominantly by nongastroenterologists (10) . Several studies (26 -28) have shown that physician specialty is associated with colonoscopy quality, with gastroenterologists outperforming physicians from other disciplines. Subsequent case-control studies from Germany and the United States, where gastroenterologists perform most colonoscopies, showed that colonoscopy was associated with decreased incidence of proximal colon cancer (6) and mortality (8, 9, 25) . To our knowledge, this is the first study to assess whether colonoscopy is associated with reduced CRC mortality in the VA health care system, the largest integrated health care system in the United States.
Our study can be compared most directly with that of Baxter and colleagues (9) , which used SEER (Surveillance, Epidemiology, and End Results)-Medicare data; both studies used a similar design and were based in the United States. In Baxter and colleagues' study, case patients who had died of CRC were less likely than matched control patients to have undergone colonoscopy (OR, 0.40 [CI, 0.37 to 0.43]); the association was stronger for distal (OR, 0.24 [CI, 0.21 to 0.27]) than proximal (OR, 0.58 [CI, 0.53 to 0.64]) cancer. The ORs reported in our study are similar despite a shorter observation time than in Baxter and colleagues' study (median, 43.5 vs. 113 months). The similar findings of the studies support the effectiveness of colonoscopy in preventing CRC death in a U.S. health care setting and are aligned with evidence that the quality of care in the VHA system, reflected by risk-adjusted mortality, is similar to that in non-VHA settings (29) . Our findings extend those of Baxter and colleagues because we showed that exposure to screening colonoscopy was also associated with significant reductions in CRC mortality. However, our subgroup analysis by colonoscopy indication was limited by the relatively small proportion (20.6%) of screening procedures. This was expected given the time frame of the study; most of the colonoscopies in our study occurred before 2007, when the VHA endorsed colonoscopy as a CRC screening option. There may be variability within the VHA system based on geographic location and resource availability that was not captured by our findings; our group is actively investigating this.
As in other studies, we found a smaller reduction in right-sided than left-sided CRC mortality. Several explanations have been proposed for the lower protection in the proximal colon. These include potentially reversible factors, such as bowel preparation quality, patient factors (diet or cigarette smoking), operator-dependent factors (cecal intubation; withdrawal time and technique; detection of adenomas, nonpolypoid neoplasms, or serrated lesions; or completeness of polypectomy), or system-related factors (financial incentives or disincentives, organizational pressures, or adequacy of equipment), as well as irreversible factors, such as altered tumor biology with accelerated progression to invasive cancer.
Similar to health care organizations in other countries (30) , the VHA has recently issued directives emphasizing the importance of high-quality CRC screening and requiring measurement and reporting of colonoscopy quality metrics (31). Knowledge of the effect of colonoscopy on patient outcomes is a fundamental component of such an initiative and is required for a health care system that provides preventive care to a large number of patients. Our findings do not answer the question of whether colonoscopy is the best CRC screening test. From the standpoint of any large integrated health care system, this issue requires not only comparison of effectiveness at the patient level but also considerations of cost, cost-effectiveness, resource availability and allocation, and patient adherence. Four ongoing randomized controlled trials (32) (33) (34) (35) (35) . These trials will provide more ORIGINAL RESEARCH Colonoscopy and Colorectal Cancer Mortality in the VA Health System definitive information on which test should be the firstline option for CRC screening in the VHA.
The rate of colonoscopy use in our study was consistent with that in prior publications, although the proportion of control patients who underwent colonoscopy (26.4%) was relatively high. This is important because in such settings, systematic differences between patients who undergo colonoscopy and those who do not may affect CRC risk (9) . Patients undergoing colonoscopy may differ in important ways, such as health-seeking behaviors and healthier lifestyles, compared with those not undergoing colonoscopy, leading to overestimation of the association between colonoscopy and reduced CRC mortality. However, our study included mostly male patients with higher prevalence of risk factors for colon neoplasia (such as cigarette smoking); greater comorbidity, as reflected by Charlson Comorbidity Index scores; and higher CRC prevalence than nonveteran populations (14) . Thus, the benefits of colonoscopy and polypectomy may be more apparent, particularly in the proximal colon. As with all observational studies, unmeasured bias and confounding may threaten the validity of our findings. We attempted to address this by determining the number of prostate-specific antigen measurements in men during the study period in order to assess propensity for health care use. Our findings suggest that case patients and control patients may not necessarily have differences in lifestyles, opportunities to undergo other health care interventions or screening, or health-seeking behaviors that are important enough to bias the results.
Our methodological approach anticipated and addressed concerns about bias and confounding in several ways. First, we matched case patients and control patients by VA facility. This was partly intended to "level the playing field" for geographic accessibility to health care. Second, we selected patients who used the VA health care system (≥2 primary care visits in the 3 years before the index date). This reduced the chance of missing exposure to colonoscopy that was performed outside the VA health care system in veterans younger than 65 years, who would not be captured in Medicare data. Third, we adjusted our analyses for several factors that are relevant to participants' health status and propensity to seek health care, including comorbidity burden and socioeconomic status.
Despite these measures, limitations remain. We could not measure potential confounding factors, such as body mass index or physical exercise. The adjudication algorithm (11) we used has sensitivity of about 70% and specificity of about 72%, so misclassification according to indication may have occurred. We could not ascertain nonprescription use of aspirin and other NSAIDs; however, we believe this was uncommon given that our patient selection strategy was "VAcentric." In addition, most patients were eligible for free care due to disability or low income and were therefore more likely to obtain medications, including aspirin and NSAIDs, from a VA pharmacy. Finally, information on procedure quality (as measured by bowel preparation adequacy, adenoma detection, and cecal intubation rates) was not available. Nevertheless, our estimates of reductions in CRC mortality are similar to those from different health care settings (9) , which supports the validity of our findings.
In conclusion, our study showed that colonoscopy was associated with a reduction in CRC mortality of approximately 60% in the VHA system, although the reduction was less pronounced in the right colon. Reducing variability in colonoscopy effectiveness, particularly against right-sided CRC, is critical for effective prevention of CRC. Data set: The authors are unable to provide access to the data because of data use agreements that prohibit disclosing data (identifiable or deidentified) outside the VHA.
